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Introduction
The	goal	of	the	Georgia	Sickle	Cell	Data	Collection	
(SCDC)	Program	is	to	improve	the	quality	of	life,	life	
expectancy,	and	the	health	of	individuals	with	sickle	
cell	disease	by	developing	and	disseminating	scientific	
evidence	to	inform	policies	and	practices.
This	longitudinal	data-collection	effort	builds	on	five	
years	of	sickle	cell	disease	surveillance	in	the	state	
created	under	cooperative	agreements	with	the	U.S.	
Centers	for	Disease	Control	and	Prevention	(CDC)	and	
the	National	Heart,	Lung,	and	Blood	Institute’s	Registry	
and	Surveillance	System	for	Hemoglobinopathies	
(RuSH)	pilot	project	and	the	CDC’s	Public	Health	
Research,	Epidemiology,	and	Surveillance	in	Hemoglobinopathies	(PHRESH)	initiative.
Georgia	collected	data	(2004-2008)	from	the	following	sources	to	develop	its	surveillance	system	for	
hemoglobinopathies:1 
• State	newborn	screening	program	(source:	Georgia	Department	of	Public	Health);
• Death	records	(source:	Georgia	Department	of	Public	Health);
• Clinical	data	from	the	three	comprehensive	sickle	cell	centers	in	the	state	(Augusta	University,	Grady	
Health	System,	and	Children’s	Healthcare	of	Atlanta);
• Administrative	claims	data	from	Georgia’s	Medicaid,	Children’s	Health	Insurance	Program,	and	the	State	
Health	Benefit	Plan	(source	for	all	three:	Georgia	Department	of	Community	Health);	and
• Hospital	and	emergency	department	(ED)	discharge	data	(source:	Georgia	Hospital	Association	under	a	
data-sharing	agreement	with	Georgia	Department	of	Public	Health).
The	current	goals	are	to	continue	using	and	improving	upon	developed	methods	and	data	sources	for	
understanding	sickle	cell	disease	at	the	population	level	in	Georgia,	including	extending	the	database	
to	include	longitudinal	data	through	2016	(or	most	recent	year	available).	This	unique	data	set	enables	
examination	of	individual-level	patient	data	for	every	health	care	system	encounter	for	more	than	10,000	
patients	over	13	years.	The	ability	to	collaborate	with	the	SCDC	project	in	California,	and	possibly	other	states	
in	the	future,	brings	additional	power	to	the	capabilities	of	the	data	set	in	its	ability	to	identify	trends	and	
inform	changes	in	both	policy	and	practice.
The	following	plan	represents	our	best-informed	strategy	for	using	the	data	over	the	next	three	years.	It	is	
based	on	substantial	input	from	sickle	cell	disease	stakeholders,	including	affected	populations,	policymakers,	
providers,	and	payers.
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Sickle Cell Disease Overview
Sickle	cell	disease	(SCD)	describes	a	group	of	
inherited	blood	disorders	that	affect	hemoglobin,	
a	protein	in	red	blood	cells	that	is	responsible	for	
carrying	oxygen	through	the	body.	A	single	gene	
mutation	causes	people	with	SCD	to	have	abnormal	
hemoglobin.	Normal	hemoglobin	has	a	disc	shape	
that	is	flexible	and	can	move	throughout	the	body’s	
blood	vessels	to	deliver	oxygen.	Instead	of	healthy,	
disc-shaped	hemoglobin,	those	with	SCD	have	sickle	
hemoglobin	that	forms	stiff	rods	with	a	crescent	
shape.	These	sickle-shaped	cells	are	not	flexible	
and	can	stick	to	the	walls	of	blood	vessels,	causing	
a	blockage	that	slows	or	stops	the	flow	of	blood.2    
This	blockage	prevents	oxygen	from	reaching	tissues	
and	organs.	This	can	cause	severe	pain	and	fatigue,	
organ	damage,	strokes,	and	even	death.
Distribution of sickle cell disease
Sickle	cell	is	a	rare	disease,	affecting	approximately	100,000	people	in	the	United	States.3		Overall,	the	
prevalence	of	SCD	has	increased	in	the	United	States	due	to	growth	of	at-risk	populations,	as	well	as	
improvements	in	patients’	life	expectancy.
In	the	United	States,	most	people	with	SCD	have	African	ancestry	or	identify	themselves	as	black,	but	SCD	
also	affects	other	groups,	including	those	of	Hispanic	origin	and	people	of	Middle	Eastern,	Asian,	Indian,	and	
Mediterranean	descent.4 
SCD	occurs	among	approximately	one	of	every	365	black	or	African-American	births	and	in	about	one	of	every	
16,300	Hispanic-American	births.3	Considerably	more	are	born	with	sickle	cell	trait,	meaning	they	are	usually	
unaffected	but	could	pass	the	condition	to	their	offspring.5 
Life expectancy
Once	considered	a	childhood	disease	because	of	
limited	survival	into	adulthood,	there	has	been	great	
improvement	in	early	SCD	survival	due	to	preventive	
care	(e.g.,	prophylactic	penicillin	and	vaccines),	
disease-remitting	therapy	(e.g.,	hydroxyurea),	and	
use	of	comprehensive	care	models.3,	6,	7,	8
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National	Institutes	of	Health,	National	Human	Genome	Research	Institute.	Sickle	
cell	disease	[Photograph].	Talking	Glossary	of	Genetic	Terms.	Retrieved	from	
https://www.genome.gov/glossary/index.cfm?id=184
In	1973,	the	average	life	span	of	a	person	with	SCD	in	
the	United	States	was	only	14	years,	with	20	percent	
of	the	deaths	occurring	in	the	first	two	years	of	life	
and	one-third	occurring	before	the	fifth	year	of	life.9  
More	recently,	population-based	surveillance	data	
from	California	and	Georgia	for	years	2004	through	
2008	show	the	all-cause	mortality	rate	for	the	SCD	
population	aged	birth	through	4	years	was	lower	
than	the	all-cause	mortality	rate	among	African-
Americans	and	similar	to	the	total	population’s	all-
cause	mortality	rates,	but	the	rate	was	higher	among	
those	with	SCD,	compared	to	both	the	African-
American	and	total	population	rates	from	ages	5	
years	through	74	years.10 
The	life	expectancy	of	a	person	with	SCD	is	now	over	
40	years.10,	11		Among	people	with	SCD,	the	average	
age	of	death	was	about	43	years	for	females	and	41	
years	for	males.	About	one	in	sixth	deaths	occurred	in	those	under	25	years	of	age,	and	nearly	half	of	all	deaths	
occurred	in	those	over	44	years	of	age.10
While	comprehensive	care	for	children	with	SCD	has	been	linked	to	improved	survival,	the	lack	of	
comprehensive	care	for	many	adults	with	SCD	may	help	explain	the	overall	increased	mortality	rate	for	this	
population	compared	to	the	general	U.S.	population	and	African-American	population.
Genetics of sickle cell disease
While	SCD	is	a	rare	disease	in	the	number	of	total	people	affected,	it	is	one	of	the	most	common	diseases	
caused	by	a	single	gene	mutation.	The	most	severe	form	of	SCD,	hemoglobin	SS	disease,	occurs	when	the	
gene	for	sickle	hemoglobin	(hemoglobin	S)	is	inherited	from	both	parents.	When	only	one	hemoglobin	S	gene	
is	inherited,	the	person	is	a	carrier	for	SCD,	or	has	sickle	cell	trait.	While	carriers	can	pass	the	hemoglobin	
S	gene	to	their	offspring,	most	with	sickle	cell	trait	are	healthy	and	asymptomatic	for	SCD,	although	some	
complications	have	been	documented.12
There	are	additional	genetic	forms	of	SCD,	with	varying	severity:13,	14,	15 
• Hemoglobin	SC	—	A	hemoglobin	S	gene	is	inherited	from	one	parent	along	with	another	abnormal	
hemoglobin	gene,	hemoglobin	C.	Hemoglobin	SC	is	usually	a	milder	form	of	SCD.
• Hemoglobin	Sβ-thalassemia	—	In	this	form	of	the	disease	a	hemoglobin	S	gene	is	inherited	from	one	
parent,	while	a	gene	for	β-thalassemia,	another	type	of	anemia,	is	inherited	from	the	other	parent.	
β-thalassemia	has	two	forms,	“0”	and	“+.”	Hemoglobin	Sβ0	thalassemia	is	a	more	severe	form	of	SCD,	
while	Hemoglobin	Sβ+	thalassemia	is	a	milder	form	of	SCD.
• Hemoglobin	SD,	SE,	SO	—	These	forms	of	SCD	inherit	one	hemoglobin	S	gene	as	well	as	a	gene	for	
another	abnormal	type	of	hemoglobin	(D,	E,	or	O).
Georgia Health Policy Center
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Figure 1.  Individuals with SCD in Georgia by Age
U.S.	Department	of	Health	and	Human	Services,	Centers	for	Disease	Control	and	
Prevention.	(2013).	Age	distribution	of	individuals	with	SCD	in	Georgia	identified	by	
RuSH	[Graph].	Sickle	Cell	Disease	in	Georgia.	Retrieved	from	https://www.cdc.gov/
ncbddd/sicklecell/documents/scd_in_ga_prov.pdf
Diagnosis
SCD	is	diagnosed	with	a	blood	test.	However,	since	
young	children	with	SCD	are	at	an	increased	risk	of	
health	problems,	even	in	infancy,	early	diagnosis	
and	treatment	are	important.	In	the	United	States,	
SCD	is	most	often	diagnosed	at	birth	during	routine	
newborn	screening	at	the	hospital.	Every	state	in	the	
United	States,	the	District	of	Columbia,	and	the	U.S.	
territories	requires	that	all	newborn	babies	receive	
screening	for	SCD.16		If	a	child	has	SCD,	parents	are	
notified	immediately,	before	the	child	has	symptoms.
Diagnosis in Georgia
The	Georgia	Newborn	Screening	Program	ensures	that	as	of	January	1998	every	newborn	in	Georgia	is	
screened	for	31	heritable	disorders	for	prompt	identification	and	treatment,	including	SCD.17 
The	Georgia	Newborn	Screening	Program	of	the	Georgia	Department	of	Public	Health	is	responsible	for	
administering	newborn	screening,	including	the	oversight	of	follow-up	programs;	monitoring	and	evaluating	
newborn	screening	practices;	managing	electronic	data	surveillance	and	tracking	systems,	including	
maintenance	of	long-term	results;	facilitating	communication	between	practitioners,	birth	hospitals,	laboratory	
personnel,	and	follow-up	teams;	providing	ongoing	education	for	practitioners;	and	reporting	results	to	state	
and	federal	officials	and	to	the	public.
Following	a	positive	hemoglobin	screening	result,	the	American	Academy	of	Pediatrics	recommends	that	
positive	screens	be	confirmed	by	3	months	of	age,	as	early	diagnosis	of	SCD	is	crucial	in	reducing	the	morbidity	
and	premature	death	associated	with	the	disease.18	In	Georgia,	the	newborn	screening	program	contracts	with	
three	teams	for	follow-up	of	positive	screens.17	Children’s	Healthcare	of	Atlanta	provides	follow-up	for	positive	
results	in	the	Metro	Atlanta	counties,	while	Augusta	University	provides	follow-up	for	all	other	counties.	The	
teams	report	abnormal	results	to	the	health	care	provider	of	record	and	parents,	ensure	timely	confirmatory	
testing,	and	provide	education	and	counseling	to	families.	(Confirmatory	testing	and	associated	family	studies	
for	hemoglobinopathy	are	provided	free	of	charge.)	Confirmed	cases	are	referred	to	the	Children	1st	program	
at	the	Georgia	Department	of	Public	Health	for	determination	of	eligibility	for	child	health	intervention	
services.
The	Sickle	Cell	Foundation	of	Georgia	is	the	third	follow-up	entity	in	Georgia,	and	it	is	responsible	for	follow-
up	of	abnormal	hemoglobin	results	that	suggest	a	carrier	or	“trait”	status	as	a	result	of	inheriting	a	single	
hemoglobin	S	gene.
Complications
SCD	is	a	lifelong	illness.	The	severity	of	the	disease	varies	widely	from	person	to	person	and	is	not	fully	
explained	by	genetics.	Triggers	for	exacerbations	and	complications	are	also	not	fully	understood,	although	
certain	self-care	factors	(e.g.,	hydration)	and	possibly	some	environmental	factors	(e.g.,	altitude,	climate,	and	
air	quality)	play	a	role.19,	20,	21,	22,	23
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Most	SCD-related	complications	result	from	the	
blockage	of	blood	vessels	from	stuck,	sickled	
hemoglobin	S.	The	lack	of	oxygen	can	cause	organ	
damage,	commonly	seen	in	the	spleen,	lungs,	
eyes,	heart,	kidney,	liver,	gallbladder,	and	joints.13,	
24	Increasingly,	it	is	recognized	that	comprehensive	
care	with	a	focus	on	preventive	efforts	can	reduce	
complications.13
The	most	common	complications	include	pain	crises	that	often	require	hospitalization;	debilitating	chronic	pain	
that	also	can	lead	to	high	health	care	utilization;	anemia,	often	severe,	due	to	the	more	frequent	breakdown	
of	fragile,	sickled	cells;	life-threatening	infections	resulting	from	SCD-related	spleen	damage;	and	stroke,	even	
in young children.13,	25,	26,	27,	28,	29	Other	complications	can	include	delayed	growth,	pregnancy	complications,	
cognitive	problems,	and	mental	health	issues.30
Care and treatment
SCD	patients	are	encouraged	to	see	their	SCD	care	providers	regularly	—	every	three	to	12	months.31		Routine	
visits	can	include	examination	and	screening,	prophylactic	medicines	and	immunizations,	diagnostic	testing,	
and	education	of	families	about	the	disease	and	what	to	watch	out	for.	Increased	use	of	regular	screenings	and	
preventive	measures	have	decreased	infections,	complications,	and	death.13,	32,	33,	34,	35 
Measures	that	have	become	the	standard	of	quality	care	include	these:
• Prophylactic	penicillin	is	recommended	in	children	to	decrease	the	rates	of	life-threatening	infections.36 
• Immunizations,	including	conjugated	pneumococcal,	meningitis,	and	influenza	type	B,	also	reduce	
serious	infections.7
• Regular screening	with	transcranial	Doppler	(TCD)	can	identify	stroke	risk,	particularly	in	children	
between	the	age	of	2	and	16	years.37,	38,	39,	40 
• Regular	blood	transfusions	for	those	at	risk	of	stroke	have	also	decreased	the	rate	of	strokes	and	
premature	death.33,	35
• Treatment	with	hydroxyurea	decreases	the	number	and	severity	of	pain	episodes	by	increasing	the	
amount	of	fetal	hemoglobin	(hemoglobin	F)	in	the	blood,	providing	some	protection	against	the	effects	
of	hemoglobin	S.41,	42,	43,	44,	45
• Stem	cell	transplants	are	the	only	cure	for	SCD,	but	they	are	limited	in	their	use	to	certain	targeted	SCD	
populations.46,	47
Other	examinations	and	screening,	including	eye	examinations,	pulmonary	hypertension	screening,	and	
cognitive	screening,	can	identify	and	treat	SCD-related	complications	earlier.
Unfortunately,	despite	a	growing	body	of	evidence	of	the	benefit	of	these	care	and	treatment	measures,	
they	are	not	fully	utilized.32		Enhanced	surveillance	of	utilization	and	quality	practice	can	inform	payers’	and	
providers’	efforts	and	ultimately	yield	enhanced	outcomes	for	patients	with	SCD.
Georgia Health Policy Center
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New treatments forthcoming
The	landscape	of	care	and	treatment	for	those	
with	SCD	is	poised	to	improve	in	the	coming	years.	
Pharmaceutical	companies	are	currently	testing	
dozens	of	compounds	in	clinical	trials	for	SCD	and	
related	conditions.	The	SCD	community	is	optimistic	
that	these	treatments	will	lead	to	increased	life	
expectancy,	lower	health	care	costs,	and	improved	
quality	of	life.49 
The	compounds	in	development,	as	well	as	drugs	
originally	developed	for	other	purposes	now	being	
investigated	in	SCD,	have	multiple	mechanisms	
of	action.	These	include	increasing	production	
of	hemoglobin	F,	targeting	oxidative	injuries	and	
inflammation,	and	reducing	cell	adhesion	among	
sickled cells.13,	50	Longitudinal	SCD	data	can	better	inform	trials	of	these	drugs	by	providing	a	baseline	measure	
of	SCD	utilization	and	outcomes	to	which	improved	treatment-related	outcomes	can	be	compared.
Transitioning care
As	noted,	decades	ago	the	most	devastating	consequences	of	SCD	were	experienced	in	childhood.	Now,	
with	advances	in	care,	the	deleterious	effects	of	SCD	are	being	borne	most	heavily	by	adolescents	and	young	
adults.	Some	of	these	ill	effects	are	directly	related	to	the	disease	—	the	longer	one	has	lived	with	SCD,	the	
more	likely	organ	damage	and	additional	disabilities	have	occurred.	Additionally,	adolescents	and	young	
adults	are	transitioning	toward	independence;	this	transition	period	has	been	shown	to	negatively	affect	self-
management	of	the	condition.
Rates	of	ED	and	hospital	utilization	are	particularly	high	among	adults	with	this	disease.	Availability	of	quality	
care,	lack	of	insurance,	and	distance	to	care	pose	barriers	to	adult	access	to	the	comprehensive	care	models	
developed	for	the	pediatric	population.51	These	challenges	are	particularly	profound	during	the	transition	years	
between	pediatric	and	adult	care,	when	increased	rates	of	SCD-related	complications	and	mortality	have	been	
seen	among	SCD	patients.51,	52	Throughout	the	nation	there	is	a	known	shortage	of	hematologists	trained	and	
willing	to	care	for	adult	SCD	patients.53 
Past Sickle Cell Disease Surveillance
The	only	existing	universal	hemoglobinopathy	screening	and	reporting	activities	in	the	United	States	are	state-
based	newborn	screening	programs.	Screening	for	SCD	has	been	included	on	all	50	states’	newborn	screening	
panels	since	2006.	However,	researchers	note	variability	across	newborn	screening	programs	with	regard	
to	the	states’	public	health	role	in	follow-up	for	detected	SCD,	as	well	as	use	of	reported	data	for	statewide	
planning,	quality	assurance,	and	policy	development	functions.54	Additionally,	newborn	screening	does	not	
capture	those	with	SCD	that	move	from	another	state,	those	born	outside	of	the	United	States,	or	older	
individuals	born	prior	to	implementation	of	universal	screening.
There	have	been	calls	for	an	improved	system	of	data	collection	in	order	to	accurately	assess	the	number	
of	individuals	with	SCD	nationwide,	understand	the	impact	of	SCD	on	the	health	care	system,	and	
strengthen	development	of	comprehensive	systems	of	care	for	those	affected	by	SCD.1,	3,	54	A	comprehensive	
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understanding	of	the	impact	of	hemoglobinopathies	
in	the	United	States	is	important	to	health	care	
providers,	researchers,	payers,	and	policymakers.
Experts	in	SCD	recognize	that	coordinated	data	
collection	has	the	potential	to	improve	the	
understanding	and	treatment	of	SCD.	Over	the	past	
several	years,	multiple	stakeholders	have	identified	
the	need	for	improved	data	collection	as	a	priority.
In	2007,	the	American	Society	of	Pediatric	
Hematology/Oncology	Sickle	Cell	Summit	identified	
population-based	surveillance	to	measure	outcomes	
as	one	of	five	major	areas	of	opportunity	for	
improving	SCD	care.55		In	2008,	the	National	Institutes	
of	Health	convened	the	Consensus	Conference	
on	Hydroxyurea	Treatment	for	Sickle	Cell	Disease,	
which	specifically	called	for	an	SCD	surveillance	
system	containing	demographic,	laboratory,	clinical,	
treatment,	and	outcome	information.56		As	a	result	of	
these	meetings,	the	National	Institutes	of	Health’s	National	Heart,	Lung,	and	Blood	Institute	and	the	Division	of	
Blood	Disorders	at	the	CDC	collaborated	to	work	toward	state-based	surveillance	for	SCD	and	thalassemia.1
RuSH
The	Registry	and	Surveillance	System	for	Hemoglobinopathies	(RuSH)	began	as	a	pilot	project	in	2010	under	
a	cooperative	agreement	between	CDC	and	the	National	Heart,	Lung,	and	Blood	Institute	with	seven	states	
to	develop	and	systematically	test	a	multisource	surveillance	system.	California,	Florida,	Georgia,	Michigan,	
New	York,	North	Carolina,	and	Pennsylvania	participated.	According	to	2008	census	data,	these	seven	states	
combined	represented	approximately	38%	of	the	total	U.S.	population,	42%	of	the	black	population,	54%	of	
the	Asian	population,	and	49%	of	the	Hispanic	population	in	the	country.1
The	overall	purpose	of	RuSH	was	to	collect	state-specific,	population-based	data	on	people	with	SCD	and	
thalassemia,	with	the	long-term	vision	that	the	knowledge	gained	would	result	in	a	better	understanding	of	
the	conditions	and,	ultimately,	improve	the	lives	of	individuals	with	hemoglobinopathies.	Specific	objectives	
included:57
• Identifying	all	individuals	in	each	state	with	an	SCD	or	thalassemia	diagnosis	using	pre-existing	data	
sources;
• Determining	how	many	people	have	SCD	or	thalassemia;
• Developing	plans	for	a	national	surveillance	system	to	gain	a	greater	understanding	of	the	health	status	
and	health	practices	of	people	living	with	SCD	and	thalassemia;	and
• Creating	and	disseminating	health	education	materials	to	increase	knowledge	and	awareness	about	SCD	
and	thalassemia	among	the	general	public.
Georgia Health Policy Center
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Figure 2. Map of RuSH Sites
U.S.	Department	of	Health	and	Human	Services,	Centers	for	Disease	Control	
and	Prevention.	(2016).	[Map	of	the	U.S.	showing	7	RuSH	sites].	Registry	and	
Surveillance	System	for	Hemoglobinopathies	(RuSH).	Retrieved	from	https://www.
cdc.gov/ncbddd/hemoglobinopathies/rush.htm
Each	state	used	a	unique	combination	of	data	
sources	for	the	project,	depending	on	the	data	
sets	they	were	able	to	access.	Newborn	screening	
records,	hospital	discharge	data,	ED	records,	death	
records,	clinical	records,	and	state	Medicaid	claims	
were	used	for	case	identification	and/or	as	sources	
of	demographic,	clinical,	and	health	care	utilization	
data.	While	the	original	intent	of	RuSH	was	to	devise	
a	standardized	data-collection	protocol,	the	same	
methods	could	not	be	used	by	all	states	because	
of	the	varying	availability	of	data	sets	and	the	
identifying	information	contained	within	those	data	
sets.
RuSH in Georgia
In	Georgia,	RuSH	data-collection	efforts	were	led	by	the	Georgia	Health	Policy	Center	at	Georgia	State	
University	on	behalf	of	the	Georgia	Department	of	Public	Health	and	in	partnership	with	the	Sickle	Cell	Disease	
Foundation	of	Georgia	and	the	comprehensive	sickle	cell	centers	at	Children’s	Healthcare	of	Atlanta,	Grady	
Health	System	(Atlanta),	and	Augusta	University	Medical	Center	(formerly	Georgia	Regents	University	Medical	
Center).
Specific	objectives	in	Georgia	included	determining	the	prevalence	of	hemoglobinopathies	(SCD	and	
thalassemia)	across	the	life	span	in	the	state,	calculating	the	annual	incidence	of	hemoglobinopathies	in	
Georgia,	describing	the	demographics	of	the	affected	populations	in	Georgia,	and	developing	and	documenting	
the	infrastructure	and	methodology	for	data	collection	to	support	possible	continuation	or	expansion	of	
surveillance	efforts.
Georgia	used	data	(2004-2008)	from	the	following	sources	to	develop	its	surveillance	system	for	
hemoglobinopathies:1
• State	newborn	screening	program	(source:	Georgia	Department	of	Public	Health);
• Death	records	(source:	Georgia	Department	of	Public	Health);
• Clinical	data	from	the	three	comprehensive	sickle	cell	centers	in	the	state	at	Augusta	University,	Grady	
Health	System,	and	Children’s	Healthcare	of	Atlanta;
• Administrative	claims	data	from	Georgia’s	Medicaid,	Children’s	Health	Insurance	Program,	and	the	State	
Health	Benefit	Plan	(source	for	all	three:	Georgia	Department	of	Community	Health);	and
• Hospital	and	ED	discharge	data	(source:	Georgia	Hospital	Association	under	a	data-sharing	agreement	
with	Georgia	Department	of	Public	Health).
Identifiers	are	collected	under	the	public	health	authority	of	the	Georgia	Department	of	Public	Health	and	are	
used	for	matching	and	deduplication	only.	Few	data	sources	included	Social	Security	numbers	or	Medicaid	
identification	numbers	consistently.	Therefore,	deterministic	matching	of	patients	was	not	feasible	for	most	
data	sets	in	Georgia.1	Each	data	set	was	deduplicated	and	data	sets	were	then	matched,	one	at	a	time,	using	a	
probabilistic	algorithm	that	assigned	differing	weights	to	identifying	variables,	such	as	date	of	birth,	patient’s	
name,	mother’s	name	(for	children),	sex,	county,	telephone	number,	and	address.
12
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 Demographics
• There are 7,299 people in Georgia living with SCD (confirmed and probable cases).
• People with SCD live in almost every county throughout Georgia.
• Those living with SCD in Georgia range in age from newborns to people over 70 years old.
• The vast majority (97% or more) of Georgia newborns with SCD are black or African-American, while 
approximately 2% are Hispanic.
• Roughly one out of every 295 black or African-American babies born in Georgia from 2004 through 
2008 had some form of SCD.
Figure 3. Number of Individuals with SCD by County
Key Findings from RuSH Analysis:1, 58
U.S.	Department	of	Health	and	Human	Services,	Centers	for	Disease	Control	and	Prevention.	(2013).	
Number	of	individuals	with	SCD	in	Georgia	counties	identified	by	surveillance	[Graph].	Sickle	Cell	Disease	
in	Georgia.	Retrieved	from	https://www.cdc.gov/ncbddd/sicklecell/documents/scd_in_ga_prov.pdf
• Probable,	or	Level	II,	cases	defined	by	administrative	records	of	health	care	encounters	consistent	
with	SCD	(two	or	more	health	care	encounters	with	SCD	ICD	code	plus	one	or	more	SCD-associated	
complication,	treatment,	or	procedure	within	a	five-year	period).	These	probable	cases	included	those	
with	a	positive	newborn	screening	test	but	no	confirmatory	testing;	clinical	determination	from	an	SCD	
comprehensive	center;	three	or	more	SCD	ICD	codes	from	Medicaid,	PeachCare,	or	the	State	Health	
Benefit	Plan	data;	or	three	or	more	SCD	ICD	codes	from	hospital	and	ED	discharge	data.				
• Possible,	or	Level	III,	cases	involved	a	smaller	number	of	health	care	encounters	with	SCD	ICD	codes	—	
either	sickle	cell	trait	ICD	code	at	two	or	more	separate	health	care	encounters	plus	one	or	more	SCD-
associated	complications,	treatments,	or	procedures,	or	a	single	health	care	encounter	with	an	SCD	ICD	
code. 
Case	definition
RuSH	established	three	levels	of	case	definitions	for	SCD	based	on	laboratory	results	and	International	
Classification	of	Diseases,	Clinical	Modification,	Ninth	Revision	(ICD-9-CM)	codes.1	Developing	these	case	
definitions	was	a	key	task	and	evolved	as	results	were	studied	and	definitions	were	validated:
• Confirmed,	or	Level	I,	cases	defined	by	laboratory	confirmation	of	SCD	genotype.	Laboratory	results	
could	be	established	either	through	confirmatory	newborn	screening	testing	or	through	genetic	and	
laboratory	testing	at	SCD	comprehensive	centers.
PHRESH
It	was	determined	that	the	health	care	utilization	and	clinical	data	gathered	during	RuSH	could	serve	as	
the	foundation	for	the	development	of	an	ongoing,	longitudinal	SCD	surveillance	system.	Expansion	of	the	
information	collected	during	the	RuSH	project	began	in	2012	with	the	launch	of	the	CDC-sponsored	Public	
Health	Research	and	Surveillance	for	Hemoglobinopathies	(PHRESH)	project.	PHRESH	focused	on	surveillance,	
as	well	as	health	promotion	and	prevention	of	complications	in	those	with	hemogloinopathies	living	in	three	
partner	states	—	California,	Georgia,	and	Mississippi.
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Health care utilization
• There are documented health care visits for 94% of the identified 7,299 Georgia residents with SCD 
between 2004 and 2008.
• Of newborns with a positive screen for SCD from 2004 through 2008, 80% were later seen at one of 
Georgia’s two pediatric sickle cell centers.
• For 26% of individuals with SCD, there were no hospitalizations during the five-year period, and 16% 
had no ED visits.
• Hospital visits, especially those to the ED, increased considerably after childhood. Children aged 0-19 
years averaged four ED visits over the five years, while those aged 20-49 years had more than 15 
emergency visits over the same period.
U.S.	Department	of	Health	and	Human	
Services,	Centers	for	Disease	Control	
and	Prevention.	(2013).	Average	number	
of	hospital	encounters	per	individual	
with	SCD,	by	age	group,	2004-2008	
[Graph].	Sickle	Cell	Disease	in	Georgia.	
https://www.cdc.gov/ncbddd/sicklecell/
documents/scd_in_ga_prov.pdf
Figure 4. Average Number of Hospital Encounters per Individual with SCD, by Age Group, 2004-2008 
PHRESH’s	primary	goals	included:59
• Developing	a	monitoring	program	within	a	defined	geographic	area	that	provides	accurate	information	
on	the	burden	of	disease	—	how	the	disease	impacts	individuals	and	communities.
• Promoting	health	and	preventing	complications	by	improving	the	quality	of	care	for	people	with	
hemoglobinopathies,	with	a	particular	focus	on	vaccinations,	early	and	continuous	screening	(e.g.,	TCD	
screening),	and	the	use	of	appropriate	treatments	(e.g.,	hydroxyurea).	These	focus	areas	align	with	
three	of	Healthy	People	2020’s	developmental	objectives	related	to	blood	disorders.
Additionally,	PHRESH	sought	to	validate	the	RuSH	methods	and	case	definitions.
PHRESH in Georgia
Through	its	participation	in	PHRESH,	Georgia	extended	its	RuSH	efforts	of	linking	health	care	utilization	to	cases	
with	confirmed	SCD	diagnosis.	During	PHRESH,	Georgia	performed	validation	studies	of	the	SCD	case	definition	
developed	during	RuSH	and	examined	the	use	of	prevention	strategies	recommended	for	sickle	cell	patients.	
Specifically,	Georgia	sought	to	—
• Demonstrate	the	feasibility	of	a	hemoglobinopathy	surveillance	program;
• Validate	case	definitions	and	methodologies	for	collection	of	surveillance	data	on	persons	with	
hemoglobinopathies;
• Derive	baseline	estimates	of	the	demographics	and	health	service	utilization	of	persons	with	
hemoglobinopathies,	with	priority	attention	to	the	Healthy	People	2020	focus	areas:
 □ Determine	the	vaccination	coverage	and	vaccine-preventable	disease	level	in	individuals	with	SCD;
 □ Determine	the	proportion	of	children	with	Hb	SS	and	Sβ°	thalassemia	screened	by	TCD	
ultrasonography	for	stroke	risk;	and
 □ Determine	the	proportion	of	adults	and	children	with	Hb	SS	and	Sβ°	thalassemia	receiving	
hydroxyurea	treatment.
• Implement	health	promotion	and	prevention	awareness	strategies	designed	to	improve	patient	care	
quality:
 □ Develop	and	disseminate	key	health	education	materials	for	persons	with	hemoglobinopathies,	
their	families,	and	health	care	providers;	and
 □ Conduct a needs	assessment	to	identify	gaps	in	knowledge	and	educational	resources	on	
appropriate	vaccinations,	early	and	continuous	screening	for	complications,	and	disease-modifying	
therapies	among	patients	and	providers.
People	with	SCD	are	living	longer,	healthier	lives,	due	in	large	part	to	advances	in	preventing	disease-related	
complications.	One	of	the	goals	of	the	PHRESH	project	was	to	find	out	how	well	these	advances	are	reaching	
affected	individuals	in	Georgia.	Using	the	linked	surveillance	data,	several	briefs	and	academic	papers	were	
published	validating	the	use	of	the	surveillance	data	to	identify	individuals	with	SCD	as	well	as	their	receipt	
of	preventive	therapies.	Furthermore,	educational	materials	highlighting	prevention	practices	appropriate	to	
those	with	SCD	were	also	disseminated	to	providers	caring	for	SCD	patients	in	Georgia.
For	the	SCDC	project,	both	Georgia	and	California	updated	their	case	definitions	based	on	these	findings.
Georgia Health Policy Center
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 Cases identified
• Across data sets, 4,288 Level 1 (confirmed), 3,011 Level 2 (probable), and 9,208 (possible) cases were 
identified in Georgia from 2004 through 2008.1 
• The majority (88%) of the 828 newborns who screened positive for sickle cell disease from 2004 
through 2008 had a documented confirmatory diagnosis at follow-up (Level 1 case). The remaining 98 
cases with positive screens, but no confirmatory test, were categorized as Level 2.
Provider information61
Based on surveys completed with 100 primarily pediatric medical practices in 48 counties that, according 
to RuSH data, contain 85% of all confirmed SCD cases in Georgia:
• SCD patients were seen in 84 of 100 surveyed medical practices;
• Only seven practices had a sickle cell specialist on staff;
• Most respondents said they refer their patients with SCD to specialists to manage all aspects of sickle 
cell care; however
• Sixteen respondents said there was no such specialist within a one-hour drive, or they were not 
 aware of one.
Health care utilization32
• Hydroxyurea was underutilized in Georgia from 2004 to 2008:
 □ Among confirmed cases with SCD types for which hydroxyurea has demonstrated benefit, the 
portion meeting clinical criteria who received hydroxyurea was 38% (36% of children, 42% of 
adults); and
 □ Overall, only 30% of individuals (29% of children, 32% of adults) who met the clinical criteria for 
hydroxyurea treatment filled a prescription.
• Initiation of TCD ultrasound screening and pneumococcal polysaccharide vaccination (PPV) in children 
from 2004 to 2008 is suboptimal in Georgia:
 □ In a cohort of 125 Georgia toddlers with SCD, 77% received their first dose of PPV vaccine at 2 
years of age; and
 □ Only 23% of these same toddlers received their first TCD screening for stroke risk at 2 years of 
age, as recommended.
Validation studies32
• Claims data appears useful to track use of TCD in children and yields similar results to chart review.
• State-based immunization registries are the most complete source of tracking immunizations for 
individuals with SCD, better than chart review and claims data.
• Validation studies of the RuSH case definition found that a simpler definition of at least three SCD-
coded encounters was just as effective as the original definition (two encounters with SCD diagnosis 
codes and at least one encounter with an SCD-associated treatment, procedure, or complication) in 
accurately identifing “probable cases” and reducing the number of missed cases.
• Based on a five-year surveillance period, using this updated case definition of at least three SCD-
coded encounters to identify SCD in administrative data is 97% accurate in identifying true cases 
while only missing approximately 4% of cases.62 
Key Findings from Georgia PHRESH Work:60
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Sickle Cell Data Collection Program in Georgia
Data Collection 
CDC	is	committed	to	continuing	and	expanding	
prior	SCD	surveillance	activities.	With	donations	
from	Pfizer	Inc.,	Global	Blood	Therapeutics,	and	
Bioverativ,	the	CDC	Foundation	has	enabled	
CDC	to	partner	with	the	California	Rare	Disease	
Surveillance	Program	and	the	Georgia	Health	
Policy	Center	to	revisit	case	definitions,	update	
surveillance	data	sets	for	the	two	states,	and	plan	
and	begin	leveraging	the	data	sets	to	improve	
policies	and	practices	on	behalf	of	the	sickle	cell	
patient	population.	As	funds	are	available,	CDC	
plans	to	support	additional	states’	efforts.	SCDC’s	
overarching	objective	is	to	collect,	synthesize,	
and	disseminate	multisource,	population-based,	
longitudinal	data	on	people	with	SCD.63	Ultimately,	this	can	enable	efforts	to:
• Establish	a	health	profile	of	the	SCD	population;
• Track	changes	in	SCD	outcomes	over	time;
• Ensure	that	credible,	scientifically	sound	information	informs	standards	of	care;
• Inform	policy	and	health	care	practices;	and
• Improve	quality	of	life,	life	expectancy,	and	health	among	those	living	with	SCD.
SCDC	maintains	the	database	and	sources	developed	in	RuSH	but	expands	the	years	for	which	data	is	collected.	
Having	data	from	2004	through	2016,	this	data	set	enables	longitudinal	examination	of	individual-level	patient	
data	for	every	health	care	system	encounter	for	more	than	10,000	patients	over	13	years.
While	this	unique	data	set	is	valuable	to	inform	the	above-stated	goals,	some	limitations	of	the	data	should	be	
noted.	The	majority	of	the	data	is	from	administrative	data	sources	(linked	hospital	discharge,	EDs,	Medicaid	
claims,	vital	records,	and	newborn	screening),	rather	than	information	collected	directly	from	patients	or	
health	care	providers.	Furthermore,	the	database	doesn’t	contain	information	from	nonhealth	agencies	(e.g.,	
school	records),	private	data	(nongovernment	insurance	claims	or	employment	records),	or	patient-reported	
measures	(e.g.,	quality	of	life	surveys).
California	and	Georgia	are	the	two	states	currently	participating	in	SCDC.	The	participants,	along	with	CDC,	plan	
to	expand	dissemination	of	findings	to	date,	including	peer-reviewed	publications,	scientific	presentations,	and	
briefs	for	targeted	audiences	based	upon	possible	output	measures,	including	demographics,	health	system	
entry	and	exit	points,	health	care	utilization,	complications,	treatment,	outcomes,	and	provider	information.	
Additionally,	with	additional	funding,	the	program	would	like	to	expand	to	include	other	states.
Georgia Health Policy Center
17
SCDC	strives	to	improve	health	outcomes	for	people	with	SCD.	By	collecting	and	analyzing	health	information	
of	patients	with	SCD	over	time,	the	program	can	identify	critical	gaps	in	diagnosis,	treatment,	and	access	
to	care	for	people	with	SCD.	Backed	by	accurate,	scientific	information,	the	SCDC	program	can	inform	
stakeholders	about	how	these	gaps	can	be	filled	through	policy	changes,	improved	health	care	practices,	and	
new	therapies.	Stakeholders	who	can	drive	changes	in	action	from	knowledge	gained	from	the	SCDC	data	
set	include	individual	health	care	providers,	health	systems,	policymakers,	payers,	and	affected	populations	
(patients	and	their	support	circles).	
CDC,	in	partnership	with	stakeholders,	established	five	priority	areas	for	SCDC	to	address.63
Where people with SCD live
SCDC	data	shows	where	patients,	health	care	providers,	
and	health	care	facilities	are	geographically	located	and	
can	help	answer	questions	related	to	access,	health	care	
utilization,	and	quality	of	care.
The	data	allows	examination	of	geographic	challenges	
in	gaining	access	to	care,	how	far	patients	travel	
for	treatment,	whether	they	are	seen	at	the	closest	
facilities	to	their	home,	the	ratio	of	identified	patients	
to	services	or	providers	in	a	given	region,	and	how	
these	geographical	factors	may	influence	utilization	by	
provider	type	(e.g.,	ED)	and	if	local	providers	treat	SCD	
patients	according	to	best	practices.
Transition from pediatric to adult care
SCDC	data	includes	information	on	utilization	(i.e.,	how	many	times	a	patient	visits	specific	types	of	providers	
or	settings,	treatments,	and	procedures)	and	health	outcomes	for	most	patients	within	a	state,	whether	or	not	
they are seen in an SCD clinic regularly.
Previous	research	has	shown	that	the	period	of	transition	from	pediatric	to	adult	care	coincides	with	the	onset	
of	the	increasing	symptom	severity	and	high	health	care	utilization,	even	for	patients	in	regions	with	high-
quality	pediatric	care.	SCDC	data	enables	examination	of	the	factors	(e.g.,	geography,	access	to	care,	insurance	
status,	preventive	care)	that	may	be	associated	with	increases	in	SCD	symptoms	and	complications	and	poorer	
outcomes	that	surface	during	the	transition	to	adult	
care.
Hispanic patients
SCDC	data	includes	reliable	information	on	ethnicity	
and	race	from	patients	with	linked	newborn	
screening	and	clinical	case	reports.	Studies	estimate	
that	about	10%	of	patients	with	SCD	in	the	United	
States	are	Hispanic.64		SCDC	enables	analysis	of	
variables	(e.g.,	geography,	utilization,	and	outcomes)	
through	the	lens	of	Hispanic	ethnicity.
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National SCDC Priority Areas
  Aging population
  Geography of population
  Hispanic SCD population
  Transition
  Utilization
Older patients
SCDC	data	includes	longitudinal	data	on	middle-aged	
patients	and	can	reliably	determine	SCD	status	even	
among	patients	who	have	relatively	few	SCD-related	
health	system	encounters.	Additionally,	SCDC	data	
includes	death	records,	with	identified	cause	of	
death.
People	with	SCD	are	living	longer,	so	we	have	the	
opportunity	to	study	them	as	they	become	older	
adults.10 Previous research has shown that in an 
SCD	cohort,	complications	and	comorbidities	were	
common	and	included	hypertension	and	diabetes,	
as	well	as	early-onset	complications,	such	as	chronic	renal	disease,	iron	overload,	and	cardiovascular	disease.52 
Additionally,	the	majority	were	not	undergoing	routine,	recommended	cancer	screenings.	SCDC	data	enables	
documentation	of	complications	and	outcomes	during	the	life	course,	which	can	inform	development	of	
standards	of	care,	interventions,	and	health	care	policy	to	serve	this	population.
Use of health care services
SCDC	data	includes	longitudinal	health	care	utilization	information	by	patient	and	across	patients.	Utilization	
measures	include	counts	of	ED	visits,	outpatient	visits	(for	those	on	Medicaid),	visits	by	type	of	provider,	and	
hospitalizations.
Previous	research	has	been	limited	in	its	capacity	to	examine	all	forms	of	health	care	utilization.	There	have	
been	some	studies	describing	ED	utilization	(29%	of	SCD	patients	had	no	ED	visits	or	hospitalizations	while	
16.9%	had	three	or	more	per	year),	looking	at	age	at	time	of	heightened	health	care	utilization	(e.g.,	during	
transition	between	pediatric	and	adult	care),	and	factors	associated	with	higher	utilization	(e.g.,	age,	disease	
severity,	greater	parental	education,	and	psychiatric	illness).26,	51,	52,	65	SCDC	data	enables	comparisons	between	
low	and	high	utilizers	by	diagnosis,	procedure	or	intervention,	and	outcomes.	It	can	also	examine	events	or	
complications	that	precede	periods	of	high	utilization.	Such	analysis	may	inform	practice	behavior	and	patient	
self-care	associated	with	improved	outcomes	at	reduced	costs.
Analysis And Dissemination Planning For Georgia
Guiding framework
The	Georgia	SCDC	project	set	out	to	create	a	three-year	plan	for	analysis	and	dissemination	activities	that	was	
both	stakeholder-informed	and	action-oriented.	These	principles	help	ensure	the	project’s	goal	that	use	of	this	
longitudinal	data	can	inform	changes	in	policies	and	practices	that	ultimately	improve	length	and	quality	of	life	
for	SCD	patients.	We	engaged	a	broad	cross	section	of	stakeholders	in	the	planning	process	to	provide	as	many	
perspectives	and	insights	as	possible	into	the	potential	for	SCDC	data	to	impact	change	and	to	build	awareness	
and	support	for	future	analysis	and	dissemination	activities.	The	identified	stakeholders	serve	both	as	research	
design	partners	and	audience	for	research	outputs.
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These	guiding	principles	of	having	a	stakeholder-
informed	and	action-oriented	plan	aligned	closely	
with	those	of	the	Patient-Centered	Outcomes	
Research	Institute	(PCORI),	so	we	developed	a	
modified	version	of	PCORI’s	Dissemination	and	
Implementation	Framework	to	guide	our	own	work.66 
PCORI’s	mission	is	to	drive	informed	health	care	
decisions	and	improve	health	care	delivery	and	
outcomes	by	producing	and	promoting	high-integrity,	
evidence-based	information.67		Central	to	this	mission	
is	PCORI’s	tenent	that	those	most	likely	to	use	the	
information	should	help	guide	the	research	process.	
To	be	effective,	dissemination	and	implementation	activities	must	reflect	the	needs	and	concerns	of	end	users.
PCORI’s	Dissemination	and	Implementation	Framework	illustrates	this	commitment	to	increase	the	awareness	
of	evidence	and	promote	its	integration	into	practice.	The	framework	focuses	on	ways	to	enhance	awareness	
and	knowledge	of	useful	and	relevant	information	(dissemination)	to	help	people	and	organizations	make	
decisions	and	put	it	into	practice	(implementation).
Effective	knowledge-sharing	starts	at	the	point	of	research	topic	selection	by	recognizing	the	need	to	
understand	the	priority	questions	that	can	inform	practice	and	improve	outcomes	and	to	identify	the	
audiences	who	will	use	this	evidence	to	make	relevant	decisions.	PCORI	defines	the	key	components	of	this	
cycle	as:66
• Stakeholders	—	All	people	and	organizations	with	a	vested	interest	in	increasing	the	quantity,	quality,	
and	timeliness	of	useful,	trustworthy	information	to	support	health	and	health	care	decisions;
• Dissemination	—	The	active	process	of	identifying	target	audiences	and	tailoring	communication	
strategies	to	increase	awareness	and	understanding	of	evidence,	and	to	motivate	its	use	in	policy,	
practice,	and	individual	choices;	and
• Implementation	—	The	iterative	process	of	integrating	evidence	into	policy	and	practice	through	
adapting	evidence	to	different	contexts	and	facilitating	behavior	change	and	decision	making	based	on	
evidence	among	individuals,	communities,	and	health	care	systems.
Georgia	SCDC’s	modified	version	of	the	PCORI	Dissemination	Framework	is	shown	in	Figure	5.
The	framework	is	presented	as	a	set	of	concentric	cycles,	showing	that	the	use	of	data	to	inform	change	is	an	
iterative	process	that	repeats	as	objectives	are	met,	new	findings	emerge,	or	important	contextual	changes	
develop.	The	outer	cycle	reflects	the	overall	steps:	identify	and	prioritize	information	needs,	produce	the	
data	and	analysis,	and	provide	quality,	targeted	information	–	ultimately	to	improve	health,	well-being,	and	
longevity	among	people	wih	SCD.	The	inside	cycle	describes	the	steps	in	greater	detail,	with	questions	framing	
the	objectives	for	each.	“Engage	individuals,	organizations,	and	communities”	is	at	the	center,	reflecting	that	
stakeholders have roles throughout the cycle.
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Sickle cell stakeholder convening
Figure	6	illustrates	the	process	the	Georgia	Health	Policy	Center	used	to	develop	the	three-year	dissemination	
and	analysis	plan	for	SCDC	Georgia	—	determining	needs,	identifying	audience	and	partners,	and	beginning	to	
inform	dissemination,	action,	and	assessment.	
The	five	topic	areas	identified	as	SCDC	priorities	nationally	provided	an	initial	foundation	for	the	plan.	
Stakeholders	were	engaged	at	to	help	develop	the	three-year	plan	for	Georgia	through	a	smaller	“design	
team”	representing	a	microcosm	of	SCD	stakeholders	and	in	a	day-long	convening	of	diverse	stakeholders	(see	
Appendix	A).	
Design	team	members	were	recruited	to	help	shape	the	convening	and	make	sense	of	its	results.	In	the	
months	prior	to	the	convening	they	met	three	times,	providing	insights,	perspectives,	and	advice	in	response	
Georgia Health Policy Center
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Adapted	from	Esposito,	D.,	Heeringa,	J.,	Bradley,	K.,	Croake,	S.,	Kimmey,	L.	(2015).	A	framework	linking	dissemination	to	action	and	results	[Flow	Chart].	PCORI	
Dissemination	&	Implementation	Framework.	Retrieved	from	http://www.pcori.org/sites/default/files/PCORI-Dissemination-Implementation-Framework.pdf
Figure 5. A Framework Linking Dissemination to Action and Results
 
to	evolving	drafts	on	the	convening’s	purpose,	intended	outcomes,	target	stakeholder	groups,	invitation	list,	
and	agenda.	The	project	team	at	the	Georgia	Health	Policy	Center	incorporated	input	and	arranged	meeting	
logistics.	
The	meeting	was	designed	to	produce	the	following:
1. Stakeholder	input	for	Georgia’s	three-year	dissemination	and	analysis	plan;
2.	 Increased	awareness	and	understanding	of	Georgia’s	SCDC	data	set;	and
3.	 New	and	stronger	connections	among	SCD	stakeholders	in	Georgia.
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	Synthesis/drafting	by	the	Georgia	Health	Policy	Center	team	
	
*	Stakeholder	group	also	includes	design	team	and	national	project	sponsors	
Stakeholder	groups	identified	for	engagement	fell	into	three	broad	categories:	those	affected	by	SCD	(e.g.,	
patients,	caregivers,	community-based	organization	representatives);	providers	(e.g.,	outreach	workers,	
clinic	nurses,	primary	care	and	emergency	physicians,	pediatric	and	adult	hematologists,	pharmacists,	and	
health	system	representatives);	and	decision	makers/decision	informers	(e.g.,	elected	officials	and	legislative	
staff,	public	and	private	payer	representatives,	public	health	personnel,	health	services	researchers,	research	
funders,	pharmaceutical	industry	representatives,	and	health	communicators).	
A	total	of	49	individuals	participated	in	the	day-long	convening,	held	outside	of	Atlanta,	Ga.	on	May	11,	2017.	
Attendees’	24	organizational	affiliations	are	listed	in	Appendix	A).	Participants	included	seven	patients	with	
SCD,	four	family	members	of	SCD	patients,	12	in	public	health,	13	clinicians,	17	researchers,	nine	from	funding	
entities,	three	in	public	policy	roles,	three	from	the	insurance	industry,	and	six	from	the	pharmaceutical	
industry.¹		Participants	were	assigned	seats	at	tables	designed	to	optimize	the	mix	of	perspectives.	After	a	
background	presentation	on	SCD	surveillance	efforts	and	orientation	to	the	SCDC	data	set,	the	remainder	of	
the	day	was	spent	in	focused	table	conversations	or	whole-room	feedback	and	discussion.	Input	was	captured	
on	individual	worksheets	and	table	flip	charts.
After	the	convening,	Georgia	Health	Policy	Center	staff	compiled	and	organized	the	output,	identified	themes,	
and	developed	a	rough	plan	draft	that	was	reflected	back	to	the	design	team	for	input	in	a	final	meeting.	That	
Figure 6. Development of Georgia SCDC Three-Year Analysis and Dissemination Plan 
feedback	was	then	incorporated	and	a	second	draft	shared	with	the	full	group	of	convening	participants	for	
final	review	and	comment.	What	follows	is	the	result	of	that	process.
Georgia Priorities, 2017-2020
Definitions of key variables
Stakeholder groups
• Affected	populations:	Patients,	caregivers,	
representative	community-based	
organizations.
• Health	systems:	Organizations	participating	in	
the	local	system	of	care.
• Payers:	Public	and	private	entities	responsible	
for	paying	for	health	care	and	defining	enrollee	benefits.
• Providers:	Direct	care	providers,	such	as	outreach	workers,	clinic	nurses,	primary	care	physicians,	ED	
physicians,	and	hematologists.
• Policymakers:	Those	responsible	for	broad-level	resource	allocation	decisions.
It	should	be	noted	that	additional	stakeholders	(including	research	funding	agencies,	philanthropies,	and	
pharmaceutical	companies)	may	find	SCDC	data	analysis	useful.	The	five	selected	stakeholders	reflect	the	
broadest	groups	with	the	most	widespread	use	for	SCDC	data	analysis.	However,	partnerships	with	other	
groups	would	be	valuable	and	welcome.
Actions that could be informed by SCDC analysis and dissemination
• Educate:	To	shape	institutional	or	individual	practices,	behaviors,	or	attitudes.
• Decide:	To	inform	policy	or	resource	allocation	decisions	or	plans.
• Learn:	To	answer	research	questions	in	order	to	inform	future	actions.
• Target:	To	define	a	population	for	receipt	of	interventions,	services,	or	education.
Nationally identified SCD priority areas (previously defined in more detail on p. 18)
• Aging:	Population	of	SCD	patients	reaching	midlife	and	beyond.
• Geography:	Demographic-related	data,	with	a	particular	emphasis	on	location.
• Hispanic:	Those	with	self-identified	Hispanic	ethnicity.
• High	utilization:	Those	using	higher	levels	of	health	care	services.
• Transition:	SCD	patients	moving	from	pediatric	to	adult	services.
Fitting SCD priorities in the national health reform landscape
Efforts	are	underway	locally,	regionally,	and	nationally	to	transform	the	health	care	system	to	be	more	efficient,	
Georgia Health Policy Center
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equitable,	and	effective.	The	Triple	Aim,	as	originally	
defined	by	the	Institute	for	Healthcare	Improvement	
in	Cambridge,	Mass.,	refers	to	the	simultaneous	
pursuit	of	improving	the	patient	experience	of	care	
(quality	of	care),	improving	the	health	of	populations	
(overall	outcomes),	and	reducing	the	per	capita	cost	
of	health	care.	In	recognition	of	these	goals,	Georgia	
SCDC	mapped	priorities	to	three	key	components	of	
the	Triple	Aim:	access,	cost,	and	quality.
Access
Inherent	in	the	pursuit	of	the	Triple	Aim	is	the	
assumption	that	patients	are	able	to	access	health	
care.	SCDC	data	includes	measures	of	many	
components	of	access,	including	geography	(the	distribution	of	SCD	patients	in	the	state	and	distribution	and	
types	of	SCD	care	providers	throughout	the	state),	and	insurance	status	of	patients.	Other	SCDC	demographic	
data	(e.g.,	age,	race)	may	also	be	helpful	in	identifying	any	gaps	in	access	to	appropriate	care.
Cost
Containing	cost	and	increasing	value	is	a	pervasive	theme	of	health	care	reform	efforts.	Public	and	private	
payers	are	in	many	cases	tying	reimbursement	to	the	quality	of	care	provided	in	order	to	ensure	that	care	is	
effective,	efficient,	and	coordinated.	The	focus	on	quality	of	care	is	placing	more	emphasis	on	evidence-based	
medicine	and	standardizing	care	as	a	way	of	enhancing	quality	and	reducing	disparities.	As	patients	are	footing	
an	increasing	share	of	health	care	bills,	they	too	are	starting	to	pay	more	attention	to	the	cost	of	care.
SCD	care	is	costly	and	plagued	with	substantial	practice	variation.32	Based	on	a	multistate,	multipayer	patient	
sample,	SCD-attributable	medical	expenditures	in	children	were	conservatively	estimated	in	2005	to	cost	$335	
million.68		Children	with	SCD	incurred	medical	expenditures	that	were	$9,369	and	$13,469	higher	than	those	
of	children	without	SCD	enrolled	in	Medicaid	and	private	insurance,	respectively,	or	six	and	11	times	those	of	
children	without	SCD	enrolled	in	Medicaid	and	private	insurance,	respectively.68	Care	is	even	more	costly	in	
adults.	Total	health	care	costs	with	SCD	rise	with	age,	from	$892	to	$2,562	per	patient-month	in	the	0-9–year	
and	50-64–year	age	groups,	respectively.69 
Extrapolated,	the	average	lifetime	of	care	for	an	SCD	patient	is	$460,151.	The	same	study	showed	that	the	
majority	of	SCD-related	health	care	costs	(80.5%)	are	associated	with	inpatient	hospitalizations.	Stakeholders	
believe	that	interventions	that	can	prevent	SCD	complications	and	hospitalizations	have	the	potential	to	reduce	
the	significant	economic	burden	of	the	disease.	Additionally,	improving	access	to	care	and	educating	patients	
about	appropriate	care	seeking	(including	self-care)	based	on	symptoms	also	have	the	potential	to	cut	SCD-
related costs.
Quality
While	the	effectiveness	of	certain	prophylactic	treatments	(hydroxyurea	and	penicillin)	and	screenings	(TCD)	
have	been	documented	in	the	literature,	the	adoption	of	these	advances	into	routine	clinical	care	is	often	
lengthy.70		Implementation	of	evidence-based	practice	standards	has	been	shown	to	improve	quality	of	care	for	
patients	with	SCD,	but,	again,	there	are	questions	about	whether	this	quality	care	is	reaching	all	SCD	patients.71 
Longitudinal	SCDC	data	enables	evaluation	of	the	adoption	of	these	promising	practices	in	real-life	settings,	
both	in	terms	of	provider	behavior	and	impact	on	patient	outcomes.
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Figure 7. SCDC Georgia Plan Aligned With Dissemination Framework
The	three-year	analysis	and	dissemination	plan	for	SCDC	Georgia	elaborates	upon	the	elements	of	the	
Framework	Linking	Dissemination	to	Action	and	Results.	The	nationally	identified	SCDC	priority	areas	served	
as	a	starting	point	for	stakeholder-identified	needs;	the	Design	Team	and	the	broader	Stakeholder	Group	
served	as	the	audience	and	partners;	the	actions	that	can	be	informed	by	SCDC	dissemination	and	analysis,	as	
identified	by	the	convening	participants	parallel	actions;	and	the	elements	of	the	triple	aim	were	selected	as	
high-level	parameters	of	impact.
Recommended dissemination activities
The	convening	yielded	an	extensive	list	of	stakeholder-identified	needs	and	potential	actions	that	can	be	taken	
by	multiple	audiences	as	a	result	of	SCDC	data	and	analysis.	The	full	list	of	Georgia	SCDC	priorities	identified	by	
convening	attendees	is	displayed	in	Appendix	B.
The	Georgia	SCDC	team	distilled	the	full	list	by:
• What	is	feasible	with	the	data	set;
• What	is	actionable	by	one	or	more	stakeholder	groups	toward	improving	length	or	quality	of	life;
• The	timeframe	(short-term	dissemination	not	requiring	extensive	analysis	and	longer-term,	more	
complex	research	questions);	and
• Priorities	within	the	SCD	community.
Georgia Health Policy Center
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Table 1. Three-Year Dissemination Opportunities by Target Audience and Priority Area 
26
Target	Audience	
Ag
in
g	
G
eo
gr
ap
hy
	
H
is
pa
ni
c	
Tr
an
si
tio
n	
U
til
iz
at
io
n	
Affected	Populations	
Target	patient	materials	on	SCD	basics	and	appropriate	use	of	health	care	through	
hospitals	and	emergency	departments	in	parts	of	state	with	high	utilization		
	 	 	 	 	
Target	SCD	patient	and	family	education	in	parts	of	state	with	high	SCD	prevalence,	
high	SCD-related	mortality,	high	complication	rates,	or	unusual	utilization	patterns	
	 	 	 	 	
Target	high-incidence	areas	for	trait	education	and	screening	
	 	 	 	 	
Target	culturally,	linguistically,	and	topically	appropriate	patient	outreach	and	
education	based	on	patient	demographics	by	geography	
	 	 	 	 	
Health	Systems	
Target	outreach/case	management	capacity	(and	ultimately	workforce/hiring	
decisions)	based	on	areas	of	greatest	service	shortage,	especially	to	ensure	access	to	
essential	follow-up	
	 	 	 	 	
Decide	allocation	of	outpatient	resources/hours	based	on	the	most	frequent	
presenting	reasons	for	ED	visits/hospitalizations	
	 	 	 	 	
Decide	location	and	hours	of	specialty	clinics	and	establishment	of	telehealth	
capabilities	based	on	accessibility	of	care	facilities	across	the	acuity	spectrum	
	 	 	 	 	
Payers	
Decide	quality	measures	to	reflect	evidence-based	practices	
	 	 	 	 	
Target	transition-appropriate	information	on	health,	benefits,	and	referrals	based	on	
areas	of	highest	transition-aged	populations	
	 	 	 	 	
Target	provider	contracts	to	ensure	in-network	care	options	(or	out-of-network	
coverage	if	no	other	option)	for	all	ages,	needs,	acuities	available	within	reasonable	
time	and	distance	of	patients	
	 	 	 	 	
Policymakers	
Decide	resource	allocation	to	make	social	services	and	supports	accessible,	based	on	
distribution	of	births	and	transition-aged	and	aging	populations	
	 	 	 	 	
Decide	workforce	development	incentives	to	reduce	provider-patient	gaps	by	
geography	
	 	 	 	 	
Target	benefits	counseling	and	referrals	for	parents	of	newborns,	transition-age	
patients,	and	adult	patients	based	on	incidence/prevalence	distributions	by	age	
	 	 	 	 	
Providers	
Target	education	of	emergency	physicians,	primary	care	providers,	OB/GYNs,	and	
hospitalists	in	areas	with	high	incidence,	prevalence,	mortality,	or	utilization	
	 	 	 	 	
Decide	referral	strategies	based	on	location	of	specialists	and	SCD	care	providers	
	 	 	 	 	
Target	culturally,	linguistically,	and	topically	appropriate	provider	education	based	
on	demographics	by	geography	
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Table	1	reflects	the	top,	short-term	dissemination	opportunities	that	can	be	completed	using	Georgia	SCDC	
within	a	three-year	timeframe.	These	prioritized	dissemination	needs	are	sorted	by	stakeholder	audience	and	
how	they	target	national	SCDC	priorities.
The	dissemination	activities	listed	in	Table	1	hinge	on	Georgia	SCDC	data	outputs	summarized	in	Table	2.	
Maps	and	tables	of	key	variables	by	geography	will	be	among	the	first	products	in	the	three-year	plan,	with	
additional	variables	by	geography	produced	as	requested	by	end	users.	Presenting	reasons	and	quality-
associated	practice	measures	are	targeted	for	Year	2.	While	the	project	team	will	proactively	produce	certain	
of	these	outputs	and	will	solicit	queries	from	and	partner	with	stakeholder	groups,	those	groups	carry	the	
primary	responsibility	for	strategically	disseminating	the	evidence	provided	and	driving	the	desired	actions.	
Table 2. Three-Year Georgia SCDC Data Outputs 
High-priority data analysis topics
Some	of	the	needs	and	opportunities	convening	stakeholders	identified	require	longer-term,	more	complex	
analysis	of	Georgia	SCDC	data.	The	Georgia	SCDC	team	removed	analysis	requests	that	were	not	feasible	with	
the	data	set	and	then	worked	with	the	design	team	to	identify	priority	research	questions	—	those	of	greatest	
immediate	need	and	potential	to	impact	change.	Design	team	members	also	noted	that	priority	should	be	
given	to	questions	that	our	longitudinal	data	is	uniquely	suited	to	answer,	ones	that	have	not	been	well	studied	
to	date,	and	ones	that	the	patient/caregiver	community	has	voiced	as	concerns.
The	resulting	priorities	are	grouped	into	three	analysis	topics:	complications	and	utilization	across	the		
pediatric-to-adult	transition,	pain	treatments	and	opioid	usage,	and	complications	and	comorbidities	in	the	
aging	population.	Table	3	demonstrates	how	the	analysis	priorities	can	inform	action	and	address	the	national	
SCDC	priorities.
Initial	studies	in	each	of	the	three	areas	can	begin	in	Year	1,	with	follow-up	analysis	in	subsequent	years	
determined	according	to	availability	of	resources,	evolving	findings	and	new	results	in	the	field,	and	ongoing	
stakeholder	input.
	SCDC	Data	Outputs	
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Geography	of	patient	demographics	(age,	race/ethnicity,	language)		 	 	 	 	 	
Geography	of	utilization	(areas	of	high	incidence,	prevalence,	
mortality,	and/or	utilization)	
	 	 	 	 	
Geography	of	providers	(locations	of	SCD	care	providers	and	
specialists;	care	facilities	across	the	acuity	spectrum)	
	 	 	 	 	
Most	frequent	presenting	reasons	for	emergency	visits	and	
hospitalizations	
	 	 	 	 	
Quality	measures	for	evidence-based	practices	 	 	 	 	 	
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Research Questions Actions to Be Informed
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Complications	and	utilization	across	pediatric-to-adult	
transition:
• What	are	the	patterns	in	complications	and	
health	care	utilization	(e.g.,	transfusion	frequency,	
prescription	filling,	outpatient	visits,	emergency	
department	visits)	across	transition?
• How	do	these	patterns	relate	to	insurance	status,	age,	
race/ethnicity,	geography?
Decisions on health 
insurance coverage 
extensions	for	young	
adults and other 
transition-supportive	
policies	and	practices
Pain	treatments	and	opioid	usage:
• Who	is	prescribing	pain	medicine	for	SCD	patients?
• Where	and	how	often	are	these	prescriptions	being	
filled?
• What	treatments	are	associated	with	lower	opioid	
prescribing?
• Does	mental	health	service	consultation	reduce	opioid	
prescribing	or	use?	
Policies	and	practices	for	
patients,	pharmacies,	
providers,	and	EDs.
Complications	and	comorbidities	in	the	aging	SCD	
population:
• What are the	patterns	in	complications	and	
comorbidities	in	the	aging	SCD	population	by	patient	
variables	(e.g.,	genotype,	race,	geography)?
• What	complications	are	predictive	of	mortality	in	
different	age	groups?
• What	complications	are	associated	with	pregnancy?
• What	are	the	patterns	in	complications	for	women	
from	pre-	to	post-menopause?	
Practice	
recommendations	for	
primary	and	specialty	
care	of	adults
    
The	convening	stakeholders	identified	a	wealth	of	relevant	research	questions	that,	given	capacity	and	funding,	
Georgia	SCDC	would	like	to	address.	Analysis	topics	not	put	in	the	first	tier	for	the	three-year	plan,	but	deemed	
important	and	doable	with	SCDC	data,	are	listed	below.	
Utilization
• Are	there	patterns	of	complications	associated	with	higher	utilization/mortality?	What	factors	are	
associated	with	hospital	readmissions?	What	factors	are	associated	with	use	of	multiple	emergency	
departments	or	multiple	health	systems?	Are	there	early	signs	of	complications	that	could	inform	
patient	self-care	practices?	Can	we	identify	people	who	are	at	high	risk	for	preventable,	poor	outcomes?	
Table 3. Priority Analysis Topics by Action and Priority Area
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• What is the cost-effectiveness	of	treating	SCD	patients	in	a	day	hospital	setting?	Are	there	differences	in	
morbidity/mortality	by	usual	care	setting	or	by	access	(cost/coverage)	to	specialists;	to	a	comprehensive	
care	center;	to	behavioral	health	care?	Are	there	differences	in	utilization	(ED,	hospital,	preventive	
services)	by	type	of	primary	SCD	provider	(specialist	or	generalist)?	Do	those	frequently	using	the	ED	
have	a	primary	source	of	SCD	care?
• Are	there	differences	in	utilization	types/frequencies	by	geographic	distance?	Does	distance	contribute	
to	use	of	ED	vs	outpatient	care?	Are	there	SCD	patients	not	seen	regularly	or	unable	to	keep	
appointments	for	whom	distance	or	transportation	might	be	a	key	barrier?
Other
• Describe	the	overall	cost	burden	of	SCD.	How	does	cost	vary	by	patient	demographics?	What	is	the	
long-term	cost-benefit	of	investment	in	preventive	strategies?	Describe	ER	cost-effectiveness	to	
support	the	need	for	enhanced	outpatient	services.	Can	ED	visits	be	mitigated	through	improved	case	
management?	Should	payment	be	tied	to	outcomes?	
• What are the trends	over	time	in	providers’	adherence	to	recommended	practices?	Are	there	commonly	
used	treatments	that	are	not	associated	with	better	outcomes?	Do	new	treatments	have	long-term	
implications	for	mortality	and	other	outcomes?
• How is it	best	to	manage	the	needs	of	dual	beneficiaries?
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Appendix A: Organizations Represented by 
Convening Attendees
A	representative	invitee	list	was	initially	developed	by	the	design	team.	If	invitations	were	declined,	invitees	
were	encouraged	to	refer	others	from	their	organization	in	order	to	achieve	balance	and	ensure	that	
representative	stakeholders	were	present	at	each	working	table.
A	total	of	49	stakeholders,	representing	24	different	organizations,	participated	in	the	convening.	Stakeholders	
attending	the	May	11,	2017,	Sickle	Cell	Stakeholder	Convening	in	Atlanta	were	roughly	evenly	representative	
of	three	broad	categories:	those	directly	affected	by	SCD	(e.g.,	patients,	caregivers,	and	representative	
community-based	organizations),	providers	(e.g.,	outreach	workers,	clinic	nurses,	primary	care,	ED	physicians,	
and	pediatric	and	adult	hematologists),	and	decision	makers/decision	informers	(e.g.,	health	services	
researchers,	health	communicators,	public	health	personnel,	payers,	research	funders,	and	legislators).	The	list	
of	represented	organizations	follows.
 
Alliant Quality Georgia	House	Budget	and	Research	Office
Amerigroup/Anthem Georgia	House	of	Representatives	(Budget	and	Research	Office)
Association	of	University	Centers	on	Disabilities Georgia	Southern	University,	College	of	Public	Health
Augusta	University Global	Blood	Therapeutics
Bioverativ Grady	Health	System
CDC Medical	College	of	Georgia,	Augusta	University
CDC	Foundation Peach State Health Plan
Children’s	Healthcare	of	Atlanta Pfizer
East	Central	Regional	Hospital Sickle Cell Awareness Ride
Emory	University Sickle	Cell	Community	Consortium
Georgia	Department	of	Public	Health	 University	of	Maryland,	School	of	Medicine
Georgia	Health	Policy	Center,	Georgia	State	University WellCare	of	Georgia	Inc.
Discussion	at	the	convening	surfaced	additional	stakeholders	whose	participation	should	be	sought.	These	
stakeholders	categorically	include:
AARP Media	and	celebrities
American	Society	of	Hematology Medical	students	and	other	emerging	professionals
Cultural liaisons Mental	health	community
Ga	Department	of	Community	Health Palliative	care	community
Ga	Department	of	Human	Services Patient	advocacy	(national	representatives)
Faith-based	community Primary	care
Hospital	association Rural	area	representatives	
Immigrant	and	refugee	community Social	workers	and	case	managers
Legislators	from	the	Health	and	Human	Services	and	
appropriations	committees
Sororities	and	fraternities
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Appendix b: Undistilled Georgia SCDC Priorities 
Identified by Convening Attendees
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